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ABSTRACT: Glucocerebrosidase (GBA) is a lysosomal β-
glucosidase that degrades glucosylceramide. Its deficiency
results in Gaucher disease (GD). We examined the effects of
active site occupancy of GBA on its structural stability. For this,
we made use of cyclophellitol-derived activity-based probes
(ABPs) that bind irreversibly to the catalytic nucleophile
(E340), and for comparison, we used the potent reversible
inhibitor isofagomine. We demonstrate that cyclophellitol
ABPs improve the stability of GBA in vitro, as revealed by
thermodynamic measurements (Tm increase by 21 °C), and
introduce resistance to tryptic digestion. The stabilizing effect
of cell-permeable cyclophellitol ABPs is also observed in intact cultured cells containing wild-type GBA, N370S GBA (labile in
lysosomes), and L444P GBA (exhibits impaired ER folding): all show marked increases in lysosomal forms of GBA molecules
upon exposure to ABPs. The same stabilization effect is observed for endogenous GBA in the liver of wild-type mice injected
with cyclophellitol ABPs. Stabilization effects similar to those observed with ABPs were also noted at high concentrations of the
reversible inhibitor isofagomine. In conclusion, we provide evidence that the increase in cellular levels of GBA by ABPs and by
the reversible inhibitor is in part caused by their ability to stabilize GBA folding, which increases the resistance of GBA against
breakdown by lysosomal proteases. These effects are more pronounced in the case of the amphiphilic ABPs, presumably due to
their high lipophilic potential, which may promote further structural compactness of GBA through hydrophobic interactions. Our
study provides further rationale for the design of chaperones for GBA to ameliorate Gaucher disease.
Lysosomal β-glucosidase glucocerebrosidase (GBA) cleavesglucosylceramide, an essential step in the turnover of
cellular glycosphingolipids.1,2 GBA is co-translationally trans-
located into the ER, where it acquires four N-linked glycans.3
After removal of its signal peptide, the 495 amino acid
polypeptide completely folds and subsequently binds to the
triple helical structure in the apical region of the integral
membrane protein LIMP-2 (lysosome integral membrane
protein 2, encoded by the Scarb2 gene), which contains
trafficking information in its cytoplasmic tail.4,5 Complexed to
LIMP2, GBA is transported through the Golgi apparatus, where
its N-linked glycans are converted into complex-type
structures.6 The GBA−LIMP2 complex is routed to late
endosomes/lysosomes, where GBA dissociates as a result of
local acid pH.5,7
GBA belongs to family 30 of glycoside hydrolase clan A
(www.cazy.org); its structural topology displays a typical (α/
β)8TIM barrel fold that forms the catalytic domain, a β-sheets
domain, and an immunoglobulin-like domain. The catalytic
domain contains several loops located in the proximity of the
enzyme’s active site.8 These seem to adopt multiple
conformations, indicating their structural flexibility and
presumably reflecting their crucial role in the enzyme’s
conformational stability and/or its substrate turnover.9
Inspection of the GBA crystal structure in complex with N-
nonyldeoxynojirimycin (NN-DNJ) (PDB code: 2V3E) shows
that the binding site of the enzyme is formed by a hydrophilic
glycon binding pocket, where the sugar ring of the inhibitor is
accommodated, forming multiple hydrogen bonds with its
surrounding residues. Also, an aglycon binding pocket is
present, formed by a narrow hydrophobic channel in which the
aliphatic tail of the inhibitor forms a cluster of hydrophobic
interactions with residues Leu241, Phe246, Tyr313, Leu314,
and Tyr244 (Figure 2d).10
Deficiency of GBA results in Gaucher disease (GD, OMIM
#203800).11 At present, more than 200 mutations in the Gba1
gene have been linked with GD, and next to truncations and
splicing defects, several hundred amino acid substitutions in
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GBA have been shown to cause GD.12 Substitutions in the
GBA polypeptide chain distant from the catalytic site
destabilized GBA’s structure, decreasing its half-life in the
cell. For instance, the L444P substitution in GBA causes faulty
folding of most of its molecules in the ER, followed by
subsequent proteasomal degradation.13 Homozygosity for
L444P GBA nearly always leads to a severe neuronopathic
course of GD, albeit with great individual variability in onset
and progression.11 Premature degradation may also occur in the
case of GBA molecules with mutations in the catalytic domain.
In fact, many of the documented mutations in GBA lead to
defective folding and reduced transport to lysosomes.14 An
exception is the N370S GBA substitution, which is the most
prevalent Gba1 mutation among caucasian GD patients. This
amino acid substitution is in a loop close to the catalytic pocket
and was found to affect the enzyme’s pH optimum and its
kinetic parameters such as affinity for substrates and
inhibitors.15−19 Notably, the intralysosomal stability of N370S
GBA is also reduced.15,16,19 The survival of wild-type GBA
within lysosomes is already relatively short (t1/2 ∼ 24−36 h), at
least in cultured cells, where its intralysosomal proteolytic
breakdown is supposedly mediated by cysteine proteases, as
suggested by inhibition studies with leupeptin.20
The major symptoms of GD are predominantly caused by
the abnormal accumulation of glucosylceramide in lysosomes of
tissue macrophages.21,22 Lysosomal accumulation of glucosyl-
ceramide induces a multisystem disorder with various
symptoms such as hepatosplenomegaly, cytopenia, and bone
disease.11 Severely affected GD patients also develop neuro-
logical symptoms, and GBA abnormalities have been
recognized as a risk factor for developing α-synucleinopathies.23
Enzyme replacement therapy (i.e., chronic intravenous
administration of macrophage-targeted recombinant human
GBA24) markedly improves visceral symptomatology in GD
patients, but the inability of the infused enzyme to pass the
blood−brain barrier prohibits the prevention and correction of
neurological manifestations.25 An alternative treatment might
be offered by so-called pharmacological chaperones that
promote the folding and stability of (mutant) GBA through
interacting with its catalytic site.26−29 These, preferably brain-
permeable, small compounds should promote the folding of
(mutant) GBA in the endoplasmic reticulum, resulting in
increased transport of GBA to the lysosome.26−29 Additionally,
pharmacological chaperones might also stabilize GBA intra-
lysosomally.15 Whether the latter is clinically beneficial is
debated since pharmacological chaperones that interact with
the active site of GBA will intrinsically also inhibit its enzymatic
activity.
Among pharmacological chaperone candidates, one of the
best studied is the iminosugar isofagamine (IFG 1). IFG 1
increased the thermal stability of GBA at neutral pH by 8.7 °C
and improved the trafficking of the N370S GBA mutant,
resulting in an increase of cellular GBA levels in Gaucher
patient tissues, including the brain.30 Additionally, oral
administration of IFG increased GBA L444P mutant activity
in mice up to 5-fold.31 Nevertheless, IFG has exhibited poor
performance when tested in humans, which could be due to its
high hydrophilicity. Therefore, several other lipophilic deriva-
tives have been tested and shown to have a higher affinity and
chaperoning activity toward GBA mutants. For example, the
GBA inhibitors N-butyldeoxynojirimycin (NB-DNJ, Miglustat)
and NN-DNJ have been applied to GD cells with relative
success: NN-DNJ has been used to restore protein levels of the
N370S GBA variant in fibroblasts and NN-DNJ has been
shown to lead to a significant increase in the protein level of
several GBA mutants in cells, with a moderate enhancement in
their thermal stability in vitro.17,32 The crystal structures of GBA
bound to IFG 1, NB-DNJ, and NN-DNJ have provided insights
into the interactions in GBA−inhibitor complexs.10,30 However,
these crystalline states did not provide a clear correlation
between the induced conformational changes in GBA upon
complex formation and the mechanism by which the inhibitors
stabilized GBA folding in solution. Therefore, we aimed to
elucidate this mechanism using reversible and irreversible
glycomimetic ligands with different lipophilic properties in vitro
and to verify our findings in vivo. Moreover, we aimed to
address the question of whether the occupancy of the binding
Figure 1. Inhibitors and reaction mechanism. (a) Structural formulas of competitive, reversible inhibitor isofagomine (IFG 1), irreversible inhibitors
conduritol β-epoxide (CBE 2), semi-irreversible inhibitor 2-deoxy-2-fluoro-β-D-glucopyranosyl-N-phenyltrifluoroacetimidate33 (fluoro 3),
cyclophellitol β-epoxide type ABP 4 (MDW933, green fluorescent), and β-epoxide-type ABP 5 (MDW941, red fluorescent).35 (b) Irreversible
binding mechanism of β-epoxide-type ABPs to the nucleophile of GBA via its double-displacement mechanism. (c) Hydrolysis of fluoro 3 and
temporary trapping of the glycosylated nucleophile adducts of GBA.
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pocket of GBA promotes its protection against proteolytic
degradation in lysosomes.
In the present study, we first examined the stabilizing effects
of cyclophellitol-type activity-based probes (ABPs; Figure 1a),
which permanently bind to the E340 catalytic nucleophile, on
pure, recombinant GBA by utilizing its double-displacement
mechanism (Figure 1b). The ABPs are β-glucose-configured
cyclophellitols with a spacer possessing hydrophobic green or
red fluorescent BODIPY moieties (MDW933 4 and MDW941
5; Figure 1a) attached to C6.33,34 We also used conduritol β-
epoxide (CBE 2) as a small hydrophilic covalent inhibitor that
is supposed to occupy only the glycon binding pocket of GBA.
By trapping GBA in its intermediate state by forming an adduct
complex with the aforementioned mechanism-based inhibitors,
we can dissect the contribution of the different moieties to the
structural stabilization of GBA through binding site occupancy.
We also examined the effect of 2-deoxy-2-fluoro-β-D-
glucopyranosyl-N-phenyltrifluoroacetimidate (fluoro 3; Figure
1a),35 which forms a transient glycosyl−enzyme intermediate
(Figure 1c), on GBA. For comparison, we studied the effect of
the potent reversible competitive GBA inhibitor IFG 1, which
has an in vitro IC50 of ∼30 nM at pH 5.2 and 5 nM at pH 7.0.
27
The various investigations are described herein, and their
implications are discussed.
■ RESULTS
Structural Stability and Flexibility of GBA: Impact of
pH and Temperature. During its life cycle, GBA is exposed
to a broad range of pH values: from neutral pH in the ER to an
increasingly acidic pH in endosomes and lysosomes (pH 6.5 to
>pH 4.5−5.0). Therefore, we first investigated the effect of
both acidic and neutral pH on the structural stability of purified
recombinant GBA (rGBA, imiglucerase) by monitoring its
thermal unfolding using circular dichroism. The dependence of
the secondary structure of rGBA on temperature was recorded
by monitoring the emission rGBA at a helical ellipticity
wavelength (222 nm) while gradually heating it from 30 to 80
°C (1 °C/min; see Figure 2a). The melting curve obtained for
rGBA at pH 7.4 shows an apparent Tm value of 57 °C, and its
melting temperature at pH 5.2 increased by 4 °C to an apparent
Tm value of 61 °C. The increase in Tm at acidic pH is in
agreement with previously reported measurements using
differential scanning calorimetry (DSC).15,32 Next, we inves-
tigated the effect of neutral and acidic pH on the activity of
rGBA in a time-dependent manner at 37 °C. For this purpose,
rGBA was first incubated for different lengths of time at 37 °C
in 150 mM McIlvaine buffer at a pH of 5.2 or 7.4. The residual
activity of rGBA was measured with the 4MU-β-D-Glc substrate
in 150 mM McIlvaine buffer at pH 5.2 (Figure 2b). The data
indicate that the activity of rGBA is preserved under acidic
conditions, whereas at pH 7.4, its activity is lost in a time-
Figure 2. pH affects the structure of rGBA. (a) rGBA melting curve at pH 5.2 (closed squares) and pH 7.4 (open circles) as determined by circular
dichroism. (b) Time-dependent decay of rGBA activity at pH 5.2 (closed squares) and pH 7.4 (open circles), as determined by hydrolysis of 4MU-β-
D-Glc substrate at pH 5.2. Data are averages of duplicate values ± SD (c) Coomassie brilliant blue staining of the time-dependent tryptic digestion of
rGBA with a trypsin/rGBA ratio of 1/10 (w/w) at pH 5.2 and 7.4 (top and bottom, respectively). The 35 kDa tryptic fragment is highlighted by an
arrow. (d) Trypsin cleavage site at lysine 233 (pink spheres) present on the flexible outer loop (red) shown on the crystal structure of GBA in
complex with NN-DNJ (PDB code: 2V3E), with NN-DNJ shown using a ball and stick model. Amino acid residues of the glycon binding pocket of
GBA are shown in blue, and residues of the aglycon site are shown in yellow. A detail view of the rendered structure is shown to the right.
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dependent manner, with a half-life of 30 min. The noted loss in
rGBA activity at pH 7.4 could be due to a loss of the enzyme’s
native fold, apparently due to an irreversible, unrecoverable
process since the remaining activity was measured at pH 5.2.
To substantiate this explanation, we performed a limited
proteolysis reaction using trypsin to probe the effects of pH on
the rigidity of rGBA. Here, rGBA was digested with trypsin in
150 mM McIlvaine buffer at pH 5.2 or 7.4, and the tryptic
events were analyzed every 10 min by SDS-PAGE (Figure 2c).
At pH 5.2, rGBA shows resistance to tryptic digestion over the
course of 90 min, whereas at pH 7.4, rGBA is more sensitive to
trypsin digestion, with about 40% degraded within 60 min. We
checked the activity of trypsin at pH 5.2 and 7.4 on
endoglucosylceramidase (EGCII) and found it to be similar
(Figure S1). Of note, a tryptic fragment of approximately 34
kDa appears during proteolysis that persists over the course of
the experiment, which may point to a structured and rigid
domain of rGBA (Figure 2c, arrow). Mass spectrometry was
used to tentatively identify the trypsin cleavage site in GBA.
The results suggest that the cleavage site position could be after
lysine 233 (UniProt: P04062) within the polypeptide sequence
VNGK_GSL, located in a loop close to the active site (Figure
S2 and Tables S1 and S2). In addition, this cleavage site seems
to be more accessible to trypsin digestion at neutral pH and
more protected at acidic pH (Figure 2d).
Thermal Stability of rGBA: Impact of Glycomimetic
Ligands. The effects of the competitive inhibitor IFG 1, the
semi-irreversible inhibitor fluoro 3, and the irreversible
inhibitors CBE 2 and lipophilic ABPs 4/5 on the thermal
stability of rGBA were investigated at pH 5.2, mimicking
lysosomal conditions. For this purpose, rGBA was incubated
with saturating concentrations of inhibitors for 1 h at 37 °C and
then gradually heated while monitoring tryptophan fluores-
cence,36,38 which decays as a result of tertiary structure
unfolding. As depicted in Figure 3a, IFG 1 increased the Tm
of rGBA (55.2 °C) by +5.6 °C, irreversible inhibitor 2, by +14.1
°C, 3, by +12.9 °C, and ABPs 4 and 5, by +21.0 and +21.7 °C,
respectively. Another analysis of biophysical stability was
performed by circular dichroism.37 rGBA without inhibitors
was compared to the enzyme saturated with 2 and β-epoxide 4
(Figure 3b). The calculated melting temperatures of rGBA
preparations follow a similar trend as that observed using
tryptophan fluorescence decay. Again, β-epoxide 4 is found to
exert the most prominent stabilization of rGBA.
Glycomimetic Ligands Influence the Intrinsic Fluo-
rescence of GBA. We next exploited the 12 tryptophan
residues present in GBA to probe the effects of ligand binding
on the general folding of GBA. Notably, Trp178 and Trp381
are in close proximity to the substrate binding pocket, and
residues Trp348 (loop 2) and Trp393 (loop 3) reside on the
Figure 3. rGBA conformational changes monitored by intrinsic fluorescence and tryptic digestion. (a) Melting temperature (Tm) determined by
tryptophan fluorescence of rGBA in the absence (control) or presence of saturating concentrations of inhibitors IFG 1, CBE 2, fluoro 3, or β-epoxide
ABPs 4 and 5. Statistical analysis of n = 3 experiments, two-way ANOVA (***, p < 0.001). (b) Tm determined by circular dichroism of rGBA in the
absence or presence of saturating concentrations of inhibitors 2 and 4. Statistical analysis of n = 2, two-way ANOVA (***, p < 0.001). (c) rGBA
fluorescence spectra at λEX 295 nm in the absence of additives (black dashed line) with a maximum λEM of 335 nm, in complex with CBE 2 (yellow)
with a maximum λEM of 333 nm, with ABP 4 (green) with a maximum λEM of 332 nm, and with ABP 5 (red) with a maximum λEM of 331 nm. (d)
rGBA fluorescence spectra showing fluorescence quenching by ABP 5 (red) with the appearance of an emission peak at 610 nm and ABP 4 (green)
with the emergence of an emission peak at 515 nm. All measurements were done in 10 mM phosphate buffer, 150 mM NaCl, pH 7.4. (e) Time-
resolved analysis of the tryptic digestion of rGBA in complex with IFG 1, CBE 2, fluoro 3, ABP 4, or ABP 5. (f) Quantification of rGBA band
densitometry during tryptic digestion in the absence (black dashed line) and presence of ABP 5 (red), ABP 4 (green), fluoro 3 (magenta), CBE 2
(yellow), or IFG 1 (cyan). Duplicate quantifications ± SD.
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protein surface; the other Trp residues are buried in the
hydrophobic core of the protein.8 rGBA emission spectra were
acquired by exciting tryptophan residues at 295 nm and
recording the emission by scanning from 300 to 450 nm in the
presence or absence of various irreversible inhibitors (Figure
3c). In its free form, rGBA exhibits a maximum emission of
336.5 nm (similar to a previously reported value38). A slight 2
nm blue shift in the spectrum was observed upon complex
formation with CBE 2, with a maximum emission at 334.5 nm,
reflective of a more hydrophobic environment of the Trp
residues within the complex state (Figure 3d). rGBA exhibits a
slightly larger blue shift when bound to ABPs 4 and 5, with
emission maxima of 333 nm. These data suggest that CBE 2
and ABPs 4/5 cause changes in the folding of rGBA, with the
stronger effects of the latter ABPs presumably being promoted
by their lipophilic tails. Serendipitously, the blue shifts induced
by ABP 4 and 5 were concomitant with fluorescence
quenching. As ABPs 4 and 5 contain a BODIPY fluorescence
moiety (green and red fluorescent, respectively), we speculate
that part of the intrinsic GBA tryptophan-emitted fluorescence
is transferred to these fluorophores through an intrinsic FRET
(iFRET) mechanism.39 To test this, the fluorescence spectra of
ABP 4- and ABP 5-labeled rGBA were acquired by exciting at
295 nm and extending the scanning range to 700 nm. Indeed,
two peaks appear (515 and 610 nm) at maximum emission,
which represent the maximum emission for both ABP-
incorporated BODIPYs (Figure 3d). This iFRET mechanism
is also supported by the overlap between the emission spectra
of rGBA and ABPs (Figure S3).
Glycomimetic Ligands Variably Rigidify the Structure
of GBA. Protein stabilization by ligands is generally paired with
protein rigidification due to new hydrogen-bond formation or
due to the formation of new clusters of hydrophobic
interactions.40 From the data presented above, we speculate
that there is a correlation between the ligand-induced
conformational changes in GBA and its thermodynamic
stabilization. We next investigated whether interactions with
(ir)reversible inhibitors stabilize GBA by rigidification in vitro;
we analyzed the effect of these inhibitors on the ability of
trypsin to digest rGBA. As depicted in Figure 3e,f, only ∼10%
of rGBA in its free form remains after 90 min of incubation, and
two major fragments are formed (∼35 and ∼40 kDa), which
remain mostly intact over the course of the experiment. The
trypsin cleavage site of the 35 kDa fragment was previously
identified to be after Lys233 (Figure S2 and Tables S1 and S2).
The presence of hydrophilic compounds IFG 1 or CBE 2
increased the resistance of rGBA against tryptic digestion, with
50% of rGBA remaining intact, and cleavage site of rGBA in its
free state by trypsin was preserved (Figure 3e,f). Fluoro 3 and
ABPs 4 and 5 exert prominent effects on the sensitivity of
rGBA to tryptic digestion (Figure 3e,f) such that within 90 min
no degradation was observed. These ABPs have long
hydrophobic tails of 15−18 Å, giving them a high lipophilic
potential. After binding to the nucleophile of GBA, the ABPs’
hydrophobic tails further rigidify GBA through hydrophobic
interactions that shield its hydrophobic core and lock into place
the flexible loop that contains the trypsin cleavage site.
Altogether, these observations match the incremental increases
in the melting temperature of rGBA between CBE 2 and ABPs
4 and 5 (Figure 3a,b). Of note, amphiphilic inhibitors 4 and 5
also show the lowest IC50 values regarding the inhibition of
GBA’s enzymatic activity, reflecting a correlation between their
stabilization effects and their high binding affinity for the
catalytic pocket (Table 1).
Lipophilic ABPs 4 and 5 Stabilize GBA in Macro-
phages and Living Mice. As ABPs 4 and 5 exerted the
strongest effect on the stability of rGBA in vitro, we assessed
their influence on the enzyme in situ. Hence, human monocyte-
derived macrophages were cultured with 100 nM ABP 5,
completely labeling all active GBA molecules (in situ IC50 ∼ 10
nM). After a continuous pulse for up to 192 h (8 days), in situ
ABP 5-labeled GBA was detected by fluorescence scanning
(Figure 4a). ABP 5 labeled various molecular weight forms of
GBA in the range 58−66 kDa, stemming from modifications in
the enzyme’s N-linked glycans.41 Earlier investigations revealed
that the 58 kDa form of GBA is formed inside lysosomes as a
result of N-linked glycans being trimmed by local glyco-
sidases.41 As seen in Figure 4a, the mature 58 kDa form of GBA
accumulates when the enzyme is labeled with 5. This finding
suggests that ABP labeling stabilizes GBA against proteolytic
degradation in lysosomes and does not prohibit N-glycan
modifications by lysosomal glycosidases.
To further examine the stabilizing effect of ABPs on GBA in
situ, we analyzed the fate of exogenous unlabeled rGBA and the
same enzyme prelabeled with ABP 4 following uptake by
human monocyte-derived macrophages (Figure 4b). The ABP
4-labeled enzyme was stable after uptake for at least 48 h, in
sharp contrast with the rapid breakdown of unlabeled rGBA
(Figure 4b). The in situ stabilizing effect was also visualized and
verified through fluorescence microscopic analyses, showing
stable ABP 4−rGBA in monocyte-derived macrophages 48 h
after uptake compared to cells loaded with rGBA (Figure 4c).
Next, we infused mice intravenously with 1 nanomole of ABP
4, which subsequently labeled endogenous GBA in various
tissues.34,35,54 In the livers of treated animals, sacrificed 6 weeks
post ABP administration, 4-labeled GBA could still be detected
(Figure 4d). The amount was around ∼35% of that in the livers
of animals that were sacrificed 24 h after infusion of an identical
dose of ABP 4 (Figure 4d, with quantification in e). This
suggests again that ABP labeling markedly stabilizes GBA in
vivo, since the half-life of unlabeled GBA is reported to be
around 32−48 h.18,20
Lipophilic ABPs 4 and 5 Increase GBA in Fibroblasts
by Protection against Lysosomal Proteolysis. To assess
whether the accumulation of ABP 4-labeled 58 kDa GBA stems
from a reduced susceptibility to lysosomal proteases, we treated
confluent human control fibroblasts for 3, 5, 7, 9, or 12 days
with the cysteine-cathepsin inhibitor leupeptin.18 After harvest-
ing the cells, GBA in the lysates of control cells and leupeptin-
exposed cells was labeled with excess ABP 4 in vitro. As shown
in Figure 5a, the amount of green fluorescent 4-labeled GBA in
untreated control cells increased slightly with culture time (top
row). The incubation of cells with leupeptin caused a
Table 1. Apparent IC50 of Inhibitors
a
compound apparent IC50 (nM)
IFG 1 31.4 at pH 5.2; 5.8 at pH 7.0
CBE 2 9497 ± 42.8
fluoro 3 5458 ± 130
ABP 4 1.24 ± 0.04
ABP 5 1.94 ± 0.08
aValues determined toward rGBA using artificial 4MUβ-D-Glc
substrate, as described earlier.54
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prominent accumulation of ∼58 kDa active GBA over time
(second row).18 Next, we incubated cells with red fluorescent
ABP 5. The inhibitor treatment induced a prominent time-
dependent accumulation of ABP-labeled GBA (third row,
Figure 5a). The increase in in situ ABP 5-labeled GBA was
slightly further enhanced in cells co-incubated with leupeptin
(fourth row), suggesting that 5-labeled GBA is still prone to
some degree of proteolysis within lysosomes (Figure 5a). The
quantification of ABP-labeled GBA is shown in Figure 5b,
indicating that the in situ stabilization of GBA by leupeptin and
ABP 5 at least partially overlap.
Lipophilic ABPs 4 and 5 Increase Mutant GBA
Molecules in GD Fibroblasts. In fibroblasts from a
homozygous N370S GBA Gaucher patient and a homozygous
L444P GBA Gaucher patient, similar stabilizing effects of ABP
on the enzyme were observed (Figure 5c). Both fibroblast cell
lines contained a lower amount of active GBA compared to the
control fibroblasts. Incubation of the cells with leupeptin and
ABP 5 resulted in the stabilization of GBA, which was more
prominent (6−8-fold) compared to that seen for GBA in wild-
type cells (about 3-fold) (compare Figure 5, panels b and d).
Exposure of both Gaucher fibroblast cell lines to the
combination of ABP 5 and leupeptin further increased the
stabilizing effect, which again partially overlapped (Figure 5d).
Total GBA protein in cell lysates was also visualized by western
blotting using the GBA-specific 8E455 antibody (Figure 5e,g,
with corresponding quantification in Figure 5f,h). Again, a
prominent stabilization of ∼58 kDa GBA was noted with ABP
5 and/or leupeptin in the case of wild-type cells and N370S
GBA Gaucher fibroblasts (Figure 5, panels f and h,
respectively). Unfortunately, comparable analysis of L444P
GBA Gaucher fibroblasts was not reliable due to the very low
quantities of GBA protein. Overall, these findings suggest that
the stabilizing effect of ABP 5 is partially caused by protection
against breakdown by lysosomal proteases. This effect is specific
since the lysosomal glycosidases processing GBA to its 58 kDa
form do not appear to be inhibited.
The reversible inhibitor IFG 1 and semi-irreversible inhibitor
3 were found to augment GBA in fibroblasts to a lesser extent.
Confluent wild-type and homozygous N370S GBA fibroblasts
were treated for 12 days with 0−100 μM 1. After harvesting,
cell lysates were labeled with excess green ABP 4 to visualize
residual active GBA molecules (Figure S4a,b). A stabilizing
effect of IFG 1 became evident only at concentrations greater
than 10 μM, being maximal at 100 μM (the highest
concentration tested). Western blot analysis of the same
experiment rendered a similar result (Figure S4c,d). The semi-
irreversible inhibitor 3 comparably augmented GBA in wild-
type and N370S/N370S GD fibroblasts (Figure S5a,b). The
findings from treating fibroblasts with 3 were confirmed by
western blot analysis (Figure S5c,d).
■ DISCUSSION
In recent years, attention has been paid to the design and
synthesis of chemical chaperones for GBA. Reviews by Benito
et al.28 and Jung et al.29 cover some of the classes of
glycomimetics currently under investigation as GBA chaper-
ones. Many of these are reversible competitive, or mixed-type,
inhibitors of GBA. The most well-studied chemical chaperone
so far has been IFG 1, which was the subject of several
preclinical studies as well as a clinical study that did not fully
meet expectations. Ambroxol,42−45 a weak, mixed-type inhibitor
of GBA, has been found to augment the enzyme in cultured
Figure 4. In situ labeling of GBA with cyclophellitol ABPs 4 and 5. (a) Continuous labeling of human monocyte-derived macrophage GBA with ABP
5 (top) and Coomassie brilliant blue (CBB) staining of protein input (bottom). (b) Chase of ABP 4 (pre-) labeled rGBA (imiglucerase) taken up by
CBE 2 pretreated human monocyte-derived macrophages (top) and CBB staining (bottom). (c) Fluorescence micrographs of macrophages in (c):
control (top) and cells treated with unlabeled rGBA (middle) and ABP 4-labeled rGBA (bottom) after 0 and 48 h (left and right, respectively).
Unlabeled rGBA was detected by labeling for 30 min with 10 nM ABP 4 prior to fixation. Scale bar represents 25 μm. (d) Chase of murine hepatic
(endogenous) GBA of animals treated either with vehicle, ABP 4 for 15 days (7 injections), or a single dose 6 weeks prior to sacrifice (top) and CBB
staining (bottom). (e) Densitometry of ABP 4-emitted fluorescence from (d), normalized using CBB, with no treatment (open circles) or treated
with repeated doses of ABP 4 (closed diamonds) or a single dose (closed squares); data are the mean of duplicate quantifications ± SEM. All gels
contain 50 fmol of equimolar ABP 4- and 5-labeled ∼59 kDa imiglucerase (asterisk) as a positive control.
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GD patient cells, and following oral administration to patients,
an impressive reduction in spleen and liver volumes was
observed. The beneficial effects of chemical chaperones on
GBA in cultured cells are generally attributed to improved
chaperone-assisted folding of GBA in the endoplasmic
reticulum. Our present investigation suggests an additional
beneficial mode of action of inhibitors, i.e., the contribution of
hydrophobic interactions in the GBA aglycon binding pocket to
its structural stability and protection against intralysosomal
proteolytic degradation.
The evidence for this notion stems from in vitro and in vivo
experiments testing GBA stabilization by inhibitors. Thermody-
namic measurements with pure recombinant GBA suggested
that all tested inhibitors stabilized the enzyme to a degree that
correlates with the strength of the inhibition. A modest
stabilization of GBA was observed for small hydrophilic
compounds IFG 1 and conduritol β-epoxide 2. The lipophilic
fluoro 3 and β-epoxides 4/5 equipped with hydrophobic
fluorophores cause a more dramatic increase in the melting
temperature of rGBA up by 21 °C. Upon complex formation
with CBE 2, GBA presents a slight shift toward the blue region
of its fluorescence spectra, an indication of a conformational
change, possibly resulting from orientation adjustments of its
indole groups toward a more hydrophobic environment. A
higher shift toward the blue region was observed when the
protein was in complex with lipophilic ABPs 4 and 5.
Presumably, their lipophilic tails cause further conformational
changes in which the indole groups of a tryptophan experience
extra hydrophobicity. Of note, equipping cyclophellitol and
cyclophellitol-aziridine with hydrophobic fluorophore tags
markedly increases their affinity for GBA.33,34 Along the same
line, Vocadlo and co-workers developed an elegant fluo-
rescence-quenched substrate for GBA by exploiting the fact that
GBA accommodates the hydrophobic ceramide moiety of
glucosylceramide, as it is known that GBA could tolerate a
hydrophobic modification in the 6-position of glucose.46 The
designed high-affinity fluorescence-quenched substrate harbors
a fluorophore attached at C6 of glucose and the hydrophobic
quencher attached to the anomeric site; to a certain extent, it
mimics fluoro 3 and ABPs 4 and 5. This successful substrate
design indicates again that the catalytic pocket of GBA
accommodates substrates possessing a hydrophobic modifica-
tion.
At present, no crystal structure of GBA has been solved in
the presence of the fluoro 3 or ABPs 4 and 5. However, the
crystal structure of GBA in complex with a lipophilic ligand
Figure 5. In situ stabilization of GBA by ABP 5 and leupeptin. Wild-type GBA fibroblasts were incubated with leupeptin, ABP 5 (red), or both for
the indicated lengths of time. (a) GBA levels in untreated fibroblasts (top row) and cells incubated with leupeptin (second row), visualized in vitro
with ABP 4 (green). Labeling of GBA in cells in situ with ABP 5 (red, third row) and in combination with leupeptin (bottom row). Equal green and
red fluorescence yields a yellow overlay; fluorescence was calibrated with 50 fmol of equimolar green ABP 4- and red ABP 5-labeled imiglucerase
present in each SDS-PAGE gel (asterisk). (b) Quantification of ABP-emitted fluorescence from in vitro ABP 4-labeled controls (open black circles),
cells treated with leupeptin only (blue triangles), cells treated with in situ ABP 5-labeled GBA (red squares), and cells treated with a combination of
ABP 5-labeled GBA and leupeptin (purple diamonds). Data are the mean of n = 2 ± SD (c) GBA levels in N370S/N370S fibroblasts treated in the
same manner as wild-type GBA fibroblasts in panel a, vide supra. (d) Quantifications of ABP fluorescence in N370S/N370S fibroblasts. (e) Detection
of total GBA protein in wild-type fibroblasts (green) by western immunoblotting of gels depicted in panel a (molecular weight ladder is in red). (f)
Quantification of total GBA protein from in vitro ABP 4-labeled controls (open black circles), cells treated with leupeptin only (blue triangles), cells
treated with in situ ABP 5-labeled GBA (red squares), and cells treated with a combination of ABP 5-labeled GBA and leupeptin (purple diamonds).
Data are the mean of n = 2 ± SD. (g) Total GBA protein in N370S/N370S fibroblasts treated in the same manner as wild-type GBA fibroblasts in
panel a, vide supra. (h) Quantifications of ABP fluorescence in N370S/N370S fibroblasts. All data are expressed as average of n = 2 ± SD.
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(NN-DNJ, PDB code: 2V3E) shows that GBA loops 1 and 2
become structured and undergo interactions with the aliphatic
tails of NN-DNJ.10 Similarly, upon complex formation with 3,
4, and 5, GBA becomes extremely protected against tryptic
digestion, providing strong evidence of its structural rigid-
ification, presumably by the formation of clusters of hydro-
phobic interactions between the tails of the ABPs and the
flexible loops in the entrance of the catalytic site of GBA.
Therefore, we presume that the observed differences of the
stabilization mechanisms between the tested compounds are
mainly due to differences in their lipophilic potential.
The predominant trypsin cleavage site in GBA’s free state is
located in a loop (residues 223−241, UniProt: P04062) close
to the active site. In solution, this loop appears to be accessible
for trypsin digestion by adopting a flexible conformation that
fits within the protease catalytic site. Protease cleavage sites
almost never occur in rigid secondary structures; they occur
largely in flexible loops.47 Interestingly, within this protein
region, 16 mutations have been reported. These have been
described to dramatically decrease GBA stability and activity,
leading to severe GD symptoms. For instance, the L224F
substitution decreases GBA activity to 4% and markedly
increases its susceptibility to proteolytic degradation.48
Mutation V230E dramatically affects GBA activity, leading to
type 1 GD disease.49 Along this line, the G232E mutation was
identified in GD patients as well as patients suffering from
Parkinson’s disease, with the mutation markedly reducing GBA
activity (∼7%) and causing severe type 2 GD.50 Moreover,
substitution of G234E in GBA’s sequence has severe affects on
the stability and catalytic activity of the enzyme.51 The position
of the latter mutation overlaps with what we describe as a major
trypsin cleavage site. On the basis of our observations, this
particular region is plausibly essential for maintaining the
correct fold of GBA’s catalytic domain. Upon complex
formation with lipophilic ABPs, this site becomes protected
against proteolytic degradation.
We recently noticed similar stabilization mechanism for
another retaining β-glucosidase, endoglycoceramidase II
(EGCII) from Rhodococcus sp.52 The stability of EGCII was
found to be improved by the formation of covalent complexes
with cyclophellitols substituted with hydrophobic moieties. The
tested compounds induced a more compact conformation of
the flexible protein structure, revealed by an increased EGCII
melting temperature, resistance against tryptic digestion,
changes in its NMR spectrum, and a decrease of its exposed
hydrophobic surface to the solvent, as determined by 8-anilino-
1-naphthalenesulfonic acid fluorescence. Stabilization of the
conformation of EGCII was correlated with the shape and
hydrophobicity of the cyclophellitols substituents. The
structural comparison between GBA and EGCII showed a
remarkable overlap of their glycon and aglycon binding
pockets.52 Therefore, the EGCII study supports the proposed
stabilization mechanism of inhibitors on the structure of GBA.
Following the observed in vitro stabilization of GBA by
inhibitors, we extended our study to living cells and mice. We
consistently noted that exposing cells (monocyte-derived
macrophages and skin fibroblasts) and mice to cyclophellitol
ABP 4 or 5 resulted in the accumulation of GBA with a
molecular weight of approximately 58 kDa, suggestive of
lysosomal localization. Co-incubation of fibroblasts with ABPs
and leupeptin, a broad lysosomal cysteine protease inhibitor
known to inhibit the proteolytic breakdown of GBA, indicated
that the stabilizing effect could indeed be partly ascribed to
reduced lysosomal breakdown. Of note, the beneficial action of
catalytic pocket occupancy by amphiphilic inhibitors on the
stability and proteolytic resistance of GBA was also observed
for N370S and L444P, two common mutations in GD.
Clearly, irreversible covalent inhibitors 4 and 5 are of no use
in the treatment of GD. However, they are valuable tools to
establish the contribution of hydrophobic interactions to GBA
stabilization and to selectively label the active form of GBA
within living cells and laboratory animals. Fluoroglucosides,
designed by Withers and co-workers,53 in theory may be more
attractive as chaperones since they initially covalently bind to
the catalytic nucleophile of a retaining glycosidase but are
ultimately released. Therapeutic application of such compounds
in patients will, however, offer the major challenge of dosing the
inhibitor adequately to reach concomitant beneficial effects in
all tissues: underdosing in a tissue will be without effect and
overdosing will cause undesired loss of degradative capacity in
addition to GBA activity inhibition. It should also be mentioned
that the natural substrate glucosylceramide may assist in the
stabilization of GBA in lysosomes. In that case, intralysosomal
GBA levels would be higher during high substrate flux, and the
prolonged absence of substrate would promote the degradation
of the enzyme. It will be of interest to examine whether a
reduction of glycosphingolipids in cells by inhibition of
glucosylceramide synthase activity is associated with increased
lysosomal turnover of GBA.
In conclusion, GBA is significantly stabilized by the dual
occupancy of its glycon and aglycon binding pockets by
amphiphilic inhibitors, likely in part by promoting a global
structural compactness of the enzyme associated with reduced
susceptibility for proteolytic cleavage by lysosomal proteases.
Our findings reveal new insights into the mechanism of
stabilization by pharmacological chaperones that could be
further exploited in the design of new compounds to rescue
GBA proteostasis in GD patients.
■ METHODS
General Methods. Isofagomine 1, fluoro 3, and ABPs 4 and 5
were synthesized as described previously.34,35,54 Chemicals were
obtained from Sigma-Aldrich if not otherwise indicated. Recombinant
GBA (rGBA, imiglucerase) was obtained from Genzyme (Cambridge,
MA, USA). Gaucher patients were diagnosed on the basis of reduced
GBA activity and demonstration of an abnormal genotype. Fibroblasts
were obtained with consent from donors. Cell lines were cultured in
Ham’s F12/DMEM (Invitrogen) supplemented with 10% (v/v) FBS.
Monoclonal anti-human GBA antibody 8E4 was produced from
hybridoma cells as described earlier.55 Buffy coats were purchased at
Sanquin Bloodbank (Amsterdam).
Cerezyme Purification. rGBA (imiglucerase) was supplied as a
sterile white lyophilized powder in the presence of mannitol and
polysorbate 80 NF as stabilizer substances. Thorough purification of
rGBA from its additives was conducted by affinity chromatography
using a Concanavalin A−Sepharose column, eluting with a 30 min
gradient of 0−1 M mannoside in 150 mM McIlvaine buffer (citric
acid−Na2HPO4, pH 5.2). Next, an additional purification step was
performed on pooled fractions using size-exclusion chromatography
(Superdex 75), and elution occurred either with 150 mM McIlvaine
buffer (citric acid−Na2HPO4, pH 5.2) or with 20 mM Tris-HCl, pH
7.4, supplemented with 150 mM NaCl. rGBA was concentrated using
Amicon Ultra-4 centrifugal filter devices (30 kDa cutoff) and kept at 4
°C for further experiments.
Limited Proteolysis. Tryptic digestion of purified rGBA with or
without reversible or irreversible inhibitors was performed at 37 °C
either in 150 mM McIlvaine buffer (pH 5.2 or 7.4) or in 20 mM Tris-
HCl, pH 7.4, supplemented with 150 mM NaCl, using a trypsin/rGBA
ratio of 1/10 (w/w) as the optimum conditions for proteolysis.
ACS Chemical Biology Articles
DOI: 10.1021/acschembio.7b00276
ACS Chem. Biol. 2017, 12, 1830−1841
1837
Digestions were stopped with cracking buffer (50 mM Tris-HCl, pH
6.8, supplemented with 1% (w/v) SDS, 25% (v/v) glycerol, 1% (v/v)
β-mercaptoethanol, and 0.05% (w/v) bromophenol blue), immedi-
ately followed by heating for 10 min at 100 °C. The tryptic digestion
products (1.5−5 μg) were separated by SDS-PAGE and analyzed by
Coomassie staining or, where stated, by fluorescence scanning (see
below). To check the effect of acidic and neutral pH on trypsin
activity, we used EGCII as a control. The same proteolysis conditions
(see above) were applied with an optimum trypsin/EGCII ratio of 1/
100 (w/w).
Tryptophan Fluorescence. rGBA (50 μM) was preincubated
with 1 mM IFG 1 or fluoro 3, 10 mM conduritol β-epoxide 2, or 100
μM cyclophellitol ABP 4 or 5 in 150 mM McIlvaine buffer (citric
acid−Na2HPO4, pH 5.2, supplemented with 0.2% (w/v) sodium
taurocholate and 0.1% (v/v) Triton X-100) for 3 h at 37 °C.
Fluorescence decay curves were obtained by diluting the rGBA−
inhibitor complex to 1 μM in Nanopure H2O, followed by
determination of tryptophane fluorescence (λEX 295 nm, slit width 5
nm; λEM 345 nm, slit width 5 nm) while the sample temperature was
increased at a rate of 1.5 °C per minute. Sample temperature was
controlled via a PTP-1 Fluorescence Peltier system (PerkinElmer). We
defined the inflection point of the temperature-induced decrease in
tryptophan fluorescence intensity as the melting temperature (Tm).
This value was determined by taking the minimum value of the first-
derivative of the slope, at which the negative slope is maximal, using
GraphPad Prism 5.1. Tryptophan emission fluorescence spectra were
mapped using λEX 295 nm (slit width 5 nm) and scanning emission at
λEM 300−470 (slit width 5 nm; Cary Eclipse fluorescence
spectrophotometer, Agilent Technologies). Samples were composed
of 5 μM purified rGBA with or without 2, 4, or 5 in 10 mM potassium
phosphate buffer (K2HPO4−KH2PO4, pH 7.4) supplemented with
150 mM NaCl. Spectral backgrounds were corrected and smoothed
using Cary Eclipse fluorescence spectrophotometer software. To
obtain the different protein−inhibitor complexes, purified rGBA was
preincubated with inhibitors in excess for 3 h at 37 °C in 150 mM
McIlvaine buffer. After labeling, excess irreversible inhibitor was
removed via buffer exchange into 10 mM potassium phosphate buffer
using Centriprep filter devices (30 kDa cutoff).
Circular Dichroism. Spectra were recorded on a Chirascan CD
spectrometer (Applied Photophysics). Far-UV CD spectra were
recorded from 180 to 300 nm in a 1 mm path length quartz cuvette
(Hellma) at 20 °C at a concentration of ca. 10 μM. Spectra were
collected for 0.5 s per data point at a 0.5 nm step size (spectral
bandwidth was 1 nm) and were corrected for background signals. A
Peltier element was used to control the sample temperature and allow
the temperature to be ramped at 1 °C per minute. The intensity of the
CD signal was monitored at various wavelengths (204, 215, and 235
nm). The unfolding transition point (Tm) of free purified rGBA at
different pH values (5.2 or 7.4) was measured by following the
ellipticity signal decay at 222 nm by applying a heating rate of 1 °C per
minute over a temperature gradient from 30 to 80 °C in 10 mM
potassium phosphate buffer (K2HPO4−KH2PO4, pH 5.2 or 7.4),
supplemented with 150 mM NaCl. The melting curves were fitted, and
the Tm’s were calculated using GraphPad Prism 5.1.
Enzyme Activity Assays. The residual β-glucosidase activity
associated with GBA was assayed at 37 °C by incubating samples with
3.75 mM 4-methylumbelliferyl-β-D-glucopyranoside (4MU-β-D-Glc) as
substrate in 150 mM McIlvaine buffer, pH 5.2, supplemented with
0.1% (w/v) BSA, 0.2% (w/v) sodium taurocholate, and 0.1% (v/v)
Triton X-100.56 The half-maximal inhibitory concentrations (IC50) of
compounds 1−5 were measured as published previously.54 The tme-
dependent decay of rGBA activity was assessed by incubating rGBA
for 0−60 min at 37 °C, and at various time points, the residual rGBA
activity was assessed by adding substrate. Assays were stopped with
excess NaOH−glycine (pH 10.3), and fluorescence was measured with
a LS30/LS55 fluorimeter (PerkinElmer) using λEX 366 nm and λEM
445 nm.
Isolation and Maturation of Macrophages. Buffy coats were
diluted into PBS supplemented with 0.1% (w/v) BSA and heparin,
subsequently layered on top of a Lymphoprep gradient (Stemcell
Technologies), and centrifuged at 1000g for 15 min at room
temperature (RT). After washing the peripheral blood mononuclear
cell pellets with PBS supplemented with 0.1% (w/v) BSA, cells were
centrifuged at 750g for 10 min at RT and rinsed, and this was repeated
at 500g for 5 min. Hereafter, the pellet was washed with
aforementioned PBS and centrifuged at 250g for 10 min at RT.
Then, monocytes were separated on a Percoll gradient. The resulting
pellet was resuspended in 2.5 mL of 60% (w/v) SIP, layered with 5 mL
of 45% (w/v) SIP and 2.0 mL of 34% (w/v) SIP, and centrifuged at
1750g for 45 min at RT. The upper interface containing monocytes
was washed thrice with the aforementioned PBS, centrifuged at 500g
for 10 min, and then centrifuged twice at 500g for 5 min. The cell
fraction was then resuspended in RPMI medium supplemented with
1% (w/v) human serum; the monocytes were counted with tryphan
blue staining, and 106 monocytes were seeded per well. After 1 h at 37
°C in a 5% (v/v) CO2 atmosphere, nonadherant nonmonocyte cells
were washed away with the aforementioned PBS and the adherant
monocytes were cultured in RPMI medium supplemented with 10%
(v/v) human serum for 7 days prior to experiment initiation.
Continuous β-Epoxide ABP 5 Pulse in Human Monocyte-
Derived Macrophages. Human monocyte-derived macrophages
were switched to X-VIVO 15 medium (Lonza) lacking human serum
and continuously pulsed with 100 nM β-epoxide ABP 5. After 0−192
h (8 days), cells were washed extensively with PBS and lysed by
scraping them in 25 mM potassium phosphate buffer (pH 6.5,
supplemented with 0.1% (v/v) Triton X-100 and protease inhibitor
cocktail (Roche)). Protein concentrations were determined, and 10 μg
of total protein (20 μL) was denatured with 5× Laemmli buffer (50%
(v/v) 1 M Tris-HCl, pH 6.8, 50% (v/v) glycerol, 10% (w/v) DTT,
10% (w/v) SDS, 0.01% (w/v) bromophenol blue), boiled for 4 min at
100 °C, and separated by electrophoresis on a 7.5% (w/v) SDS-PAGE
gel running continuously at 90 V.34,35,54−56 Wet slab gels were scanned
for fluorescence using a Typhoon variable mode imager (Amersham
Biosciences) using λEX 488 nm and λEM 520 nm (band pass filter 40
nm) for green fluorescent fluoro ABP 3 and β-epoxide ABP 4 and λEX
532 nm and λEM 610 nM (band pass filter 30 nm) for red fluorescent
β-epoxide ABP 5. ABP-emitted fluorescence was quantified using
ImageJ software (NIH, Bethesda, USA) and verified in-gel by the
presence of 50 fmol of equimolar green β-epoxide ABP 4- and red
ABP 5-labeled imiglucerase. After fluorescence scanning, SDS-PAGE
gels were fixed (50/40/10 MeOH/H2O/HAc) for 1 h, stained for
total protein (50/40/10 with 1% (w/v) CBB-G250), and destained
(45/45/10). Coomassie brilliant blue-stained gels were scanned on a
flatbed scanner.
Determination of in Situ IC50. Confluent human skin control
fibroblasts with wild-type GBA were incubated with 0−100 μM IFG 1,
0−10 μM fluoro ABP 3, or 0−100 nM β-epoxide ABP 4 for 2 h at 37
°C, and GBA-associated β-glucosidase activity was subsequently
determined by incubating them in the presence or absence of 250
μM fluorescein-di-β-D-glucopyranoside (FDG) for 1 h at 37 °C. Next,
cells were suspended by trypsinization, fixed in 3% (w/v) p-
formaldehyde, and analyzed by FACS using the FL1 channel (λEX
488 nm) of a FACSCalibur (BD Biosciences). In the case of reversible
inhibitor 1, all procedures, including washing with PBS, occurred in
the presence of 1 at the concentration employed during the in situ
incubation.
Pulse−Chase of Exogenous GBA. rGBA (imiglucerase, 50 μM)
was incubated with(out) 100 μM ABP 4 for 1 h in 150 mM McIlvaine
buffer, pH 5.2, supplemented with 0.2% (w/v) sodium taurocholate
and 0.1% (v/v) Triton X-100, at 37 °C and cleaned three times over a
30 kDa cutoff filter with PBS. Mature human monocyte-derived
macrophages were incubated with 300 μM 2 for 2 h; cells were then
washed extensively with PBS, incubated with 100 nM rGBA (control)
or 4-labeled rGBA with for 30 min at 37 °C, and again washed
extensively; the medium was then refreshed. After 0−48 h, cells were
again washed extensively with PBS and lysed by scraping in 25 mM
potassium phosphate buffer (pH 6.5, supplemented with 0.1% (v/v)
Triton X-100 and protease inhibitor cocktail (Roche)). Protein
concentrations were determined in the lysates, and of the control
rGBA-treated cells, 10 μg of total protein was labeled in vitro with 1
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μM β-epoxide ABP 4 in McIlvaine buffer, pH 5.2, and with
supplements, for 1 h at 37 °C. Finally, samples were denatured, and
4-labeled proteins were visualized by fluorescence scanning of the
SDS-PAGE slab gels. ABP-emitted fluorescence was quantified using
ImageJ software (NIH, Bethesda, USA), vide supra.
Pulse−Chase of GBA in Living Animals. The appropriate ethics
committee for animal experiments approved all experimental
procedures. C57BL/6J mice were obtained from Charles River
(Wilmington, MA, USA) and fed a commercially available lab diet
(CRM(E), Special Diet Services, UK). Two male C57BL/6J mice were
injected intravenously via the tail vein with a single dose of 100 μL of
PBS, four were injected with 100 μL of PBS containing 100 pmol of
ABP 4 (∼2 μg kg−1) 6 weeks prior to sacrifice, and four mice received
the same dose every 48 h for 15 days prior to sacrifice. At the
termination of the experiment, the mice were anesthetized with FFM
mix (25/25/50 fentanyl citrate/midazolam/H2O) and then perfused
via the heart into the aortic root with PBS, flowing at 3.0 mL min−1,
using a syringe pump (Harvard apparatus, Holliston, MA, USA). The
liver was collected and directly frozen in liquid nitrogen. Homogenates
were made in 25 mM potassium phosphate buffer, pH 6.5,
supplemented with 0.1% (v/v) Triton X-100, and ABP 4-labeled
GBA in 10 μg of total protein was analyzed via SDS-PAGE. After
fluorescence scanning, SDS-PAGE gels were fixed and stained with
CBB, vide supra.
Pulse−Chase of Normal and Gaucher Patient Skin Fibro-
blasts. Confluent human skin fibroblasts homozygous for wild-type,
N370S, or L444P GBA were cultured with medium supplemented
with 100 nM ABP 5, 100 μM leupeptin, or both components. Medium
was completely refreshed every fortnight, and after 0−12 days, cells
were lysed by scraping in 25 mM potassium phosphate buffer (pH 6.5,
supplemented with 0.1% (v/v) Triton X-100 and protease inhibitor
cocktail (Roche)). After determination of the protein concentration,
10 μg of total protein was incubated with 100 nM ABP 4 (if fibroblasts
were not treated by β-epoxide ABP 5 in situ) dissolved in 150 mM
McIlvaine buffer (pH 5.2, supplemented with 0.2% (w/v) sodium
taurocholate, 0.1% (v/v) Triton X-100, and protease inhibitor cocktail
(Roche)) for 1 h at 37 °C. Finally, samples were analyzed by SDS-
PAGE on two gels: one for fluorescence scanning followed by CBB
staining and one for western blotting; this was accomplished by
transferring the protein in the gel to a membrane for 1 h at 12 V,
followed by blocking the membrane with 2% (w/v) BSA in TBST
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% (v/v) Tween-
20), incubating the membrane with a 1:1000 diluted primary mouse α-
human GBA monoclonal antibody (8E4, 2% (w/v) BSA in TBST),
washing with TBST for 20 min (repeated 6 times), incubating with a
1:10000 diluted secondary rabbit α-mouse IRD680 antibody (Cell
Signaling, 2% (w/v) BSA in TBST), subsequent washing with TBST
for 20 min (repeated 6 times), and reading the signal on an Odyssey
infrared scanner (LI-COR). Fluorescence emitted by either ABP-
labeled proteins or antibodies was quantified using ImageJ software
(NIH, Bethesda, MD, USA), vide supra.
In Situ Treatment with IFG 1 or Fluoro 3. Confluent human
skin fibroblasts homozygous for wild-type, N370S, or L444P GBA
were incubated for 12 days with 100 nM ABP 5, 100 μM leupeptin, or
both or with 0.001−100 μM IFG 1 or fluoro 3. Medium was
completely refreshed every fortnight, and samples were treated as
described earlier, vide supra.
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acschem-
bio.7b00276.
Coomassie stained gel showing tryptic digestion of
EGCII; SDS-PAGE of GBA’s peptide profile; LC-MS
identification of peptides in bands 1 and 3; absorption
spectra of free ABPs 4 and 5 versus the emission
spectrum of unlabeled rGBA; in situ stabilization of GBA
by IFG 1 and fluoro 3 (PDF)
■ AUTHOR INFORMATION
Corresponding Authors
*E-mail: w.kallemeijn@imperial.ac.uk (W.W.K.).
*E-mail: j.m.f.g.aerts@lic.leidenuniv.nl (J.M.F.G.A.).
ORCID
Wouter W. Kallemeijn: 0000-0002-3660-2930
Martin D. Witte: 0000-0003-4660-2974
Herman S. Overkleeft: 0000-0001-6976-7005
Present Addresses
#(W.W.K.) Department of Chemistry, Imperial College
London, London, United Kingdom.
○(M.T.C.W. and M.D.W.) Department of Chemical Biology,
Stratingh Institute for Chemistry, University of Groningen, The
Netherlands.
Author Contributions
⊥F.B.B. and W.W.K. contributed equally to this work.
Notes
The authors declare the following competing financial
interest(s): J.M.F.G.A. and H.S.O. are inventors on a patent
application on cyclophellitol epoxide ABPs. The name of the
patent is Activity Based Probes (ABPs interacting with
glycosidases), and the patent number is US 9,056,847 B2
(date of patent: June 16, 2015).
■ ACKNOWLEDGMENTS
This work was supported by The Netherlands Organization for
Scientific Research (NWO-CW ChemThem “Chemical biology
of glucosylceramide metabolism”), the European Research
Council (ERC) (ERC AdvGr CHEMBIOSPHING), and
NOW research school NRSCB, grant number 022.004.027 to
H.S.O.
■ REFERENCES
(1) Brady, R. O., Kanfer, J. N., Bradley, R. M., and Shapiro, D. (1966)
Demonstration of a deficiency of glucocerebroside-cleaving enzyme in
Gaucher’s disease. J. Clin. Invest. 45, 1112−1115.
(2) Patrick, A. D. (1965) A deficiency of glucocerebrosidase in
Gaucher’s disease. Biochem. J. 97, 17C−18C.
(3) Berg-Fussman, A., Grace, M. E., Ioannou, Y., and Grabowski, G.
A. (1993) Human acid beta-glucosidase. N-glycosylation site
occupancy and the effect of glycosylation on enzymatic activity. J.
Biol. Chem. 268, 14861−14866.
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